search button
Open Access

Pirfenidone ameliorates the formation of choroidal neovascularization in mice

  • Authors:
    • Yueqi Bao
    • Lili Huang
    • Xiaobo Huang
    • Chuang Gao
    • Yu Chen
    • Liucheng Wu
    • Shunxing Zhu
    • Yu Song

  • View Affiliations

  • Published online on: February 27, 2020     https://doi.org/10.3892/mmr.2020.11007
  • Pages: 2162-2170

  • Copyright: © Bao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The formation and development of choroidal neovascularization (CNV) is accompanied by inflammation and fibrosis. Existing treatments are expensive and can cause irreversible complications. Pirfenidone (PFD) exerts anti‑inflammatory and anti‑fibrotic effects; however, its applications in the eye remain unclear. Male C57BL/6J mice (aged 6‑8 weeks) were used to explore whether PFD can inhibit the formation of laser‑induced CNV. The localization of transforming growth factor β2 (TGFβ2) was determined through immunofluorescent staining. After laser photocoagulation, the vehicle and PFD groups were intravitreally injected with 1 µl PBS and 1 µl 0.5% PFD, respectively. At day 7 after intravitreal injection, the expression of TGFβ2 and vascular endothelial growth factor (VEGF) was assessed. Fundus fluorescein angiography was performed to investigate the extent of fluorescence leakage, and the CNV areas were analyzed using a choroidal flat mount. The results demonstrated that, on day 7 after photocoagulation, the expression of TGFβ2 and VEGF was reduced in the experimental group. In addition, fluorescein angiography showed that the leakage area of CNV was significantly smaller in the PFD injection group than those observed in the control and vehicle groups. Moreover, the areas of CNV in the PFD injection group were smaller compared with those reported in the other two injection groups. Histopathological and TUNEL analyses performed on day 28 revealed that there were no notable abnormalities on the layers of the neural retina of PFD‑treated mice. In conclusion, intravitreal injection of PFD inhibited the formation of CNV in mice, likely via the downregulation of VEGF and TGFβ2, which did not cause damage to the mouse retina after 28 days of treatment.
View Figures
View References

Related Articles

Journal Cover

May-2020
Volume 21 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Bao Y, Huang L, Huang X, Gao C, Chen Y, Wu L, Zhu S and Song Y: Pirfenidone ameliorates the formation of choroidal neovascularization in mice. Mol Med Rep 21: 2162-2170, 2020
APA
Bao, Y., Huang, L., Huang, X., Gao, C., Chen, Y., Wu, L. ... Song, Y. (2020). Pirfenidone ameliorates the formation of choroidal neovascularization in mice. Molecular Medicine Reports, 21, 2162-2170. https://doi.org/10.3892/mmr.2020.11007
MLA
Bao, Y., Huang, L., Huang, X., Gao, C., Chen, Y., Wu, L., Zhu, S., Song, Y."Pirfenidone ameliorates the formation of choroidal neovascularization in mice". Molecular Medicine Reports 21.5 (2020): 2162-2170.
Chicago
Bao, Y., Huang, L., Huang, X., Gao, C., Chen, Y., Wu, L., Zhu, S., Song, Y."Pirfenidone ameliorates the formation of choroidal neovascularization in mice". Molecular Medicine Reports 21, no. 5 (2020): 2162-2170. https://doi.org/10.3892/mmr.2020.11007